ProCE Banner Activity

CME

Key Studies in Breast, Gynecologic, Renal Cell, Urothelial, Lung, Hepatobiliary, and Skin Cancers: CCO Independent Conference Highlights of the 2022 ESMO Congress

Text Module

Gain expert perspectives on the most clinically relevant data on breast gynecologic renal cell urothelial lung hepatobiliary and skin cancers presented at the 2022 ESMO Congress.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: November 14, 2022

Expiration: November 13, 2023

No longer available for credit.

Share

Faculty

Nicoletta Colombo

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Robert Motzer

Robert Motzer, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Sapna P. Patel

Sapna P. Patel, MD

Chair, SWOG Melanoma Committee
SWOG Cancer Research Network
Associate Professor, Director of the Uveal Melanoma Program
The University of Texas MD Anderson Cancer Center
Houston, Texas

David Planchard

David Planchard, MD, PhD

Head of Thoracic Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Rachna Shroff

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for global physicians and other healthcare professionals who care for patients with cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with cancer
  • Identify subpopulations of patients with cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Evaluate new data on novel agents and therapeutic approaches for patients with cancer
  • Appraise how new trial findings might affect treatment of cancer clinical practice in the future

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Nicoletta Colombo, MD:consultant/advisor/speaker: AstraZeneca, Clovis Oncology, Eisai, GlaxoSmithKline, Immunogen, Mersana, MSD/Merck, Novartis, Nuvation Bio, Onxerna, Pfizer, Pieris, Roche; researcher: AstraZeneca, Roche.

Robert Motzer, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Robert Motzer, MD:consultant: Aveo, Eisai, Exelixis, Genentech, Merck, Roche.

Sapna P. Patel, MD

Chair, SWOG Melanoma Committee
SWOG Cancer Research Network
Associate Professor, Director of the Uveal Melanoma Program
The University of Texas MD Anderson Cancer Center
Houston, Texas

Sapna P. Patel, MD: consultant/advisor/speaker: Bristol-Myers Squibb, Castle Biosciences, Delcath, Immatics, Immunocore, Merck, Novartis, Reata, TriSalus Life Sciences; stock/stock options: Amgen, Pfizer; other financial or material support: Bristol-Myers Squibb, Cardinal Health, Foghorn Therapeutics, Ideaya, InxMed, Merck, Novartis, NCI, Provectus, Seagen, Syntrix Bio, TriSalus Life Sciences.

David Planchard, MD, PhD

Head of Thoracic Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

David Planchard, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Novartis, Pfizer, Roche.

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS: consultant/advisor/speaker: Astellas, AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, EMD Serono, Exelixis, IMV Inc., Infinity Pharma, Janssen, MEI, Merck, Natera, Pfizer, Regeneron, Seagen; researcher: Astellas, Bristol-Myers Squibb, Genentech, Merck.

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Rachna Shroff, MD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, CAMI, Clovis, Genentech, Incyte, QED; researcher: Bayer, Bristol-Myers Squibb, Exelixis, IMV Inc., Loxo, Merck, Novocure, Nucana, Pieris, QED, Rafael, Seagen, Taiho, Zymeworks.

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH:consultant/advisor: 4D Pharma, ARC Therapeutics, AstraZeneca, Athenex, BeyondSpring, Blueprint Medicines, Bristol-Myers Squibb, Certara, Chugai, CytomX, Daiichi Sankyo, Eisai, Ellipses, Genentech/Roche, Gilead, Infinity, Lilly, Merck, Mersana, Myovant, Novartis, Odonate, OncoSec Medical, OncXerna, Pfizer, Reveal Genomics, Sanofi, Seagen, Umoja, Zentalis, Zetagen, Zymeworks; researcher: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer, Sanofi, Seagen.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 14, 2022, through November 13, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the understanding of healthcare professionals globally on recent practice-changing clinical data on the treatment of patients with cancer.